TSE:3407Chemicals
Assessing Asahi Kasei (TSE:3407) Valuation After AK1960 Enters Phase I Trials
Asahi Kasei (TSE:3407) is back on investors’ radar after its pharma arm and Alchemedicine moved endothelin A receptor antagonist AK1960 into Phase I trials for refractory conditions such as chronic kidney disease.
See our latest analysis for Asahi Kasei.
Those healthcare moves sit alongside fresh earnings guidance and recent results. The market has responded with a strong 30 day share price return of 16.66% and a 1 year total shareholder return of 81.82%, suggesting momentum has been building...